Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ME1111 in mild to moderate onychomycosis
NCT02022215Phase 2Completed
- Sponsor
- Meiji Seika Pharma Co., Ltd.
- Start
- Dec 2013
- Primary completion
- Oct 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ME1111 in onychomycosis, sponsored by Meiji Seika Pharma Co., Ltd.. Started Dec 2013; status: completed.
02
Drugs
ME1111
03
Conditions
onychomycosis
Beyond the preview
Go deeper on NCT02022215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02022215.